Coya Therapeutics (COYA) EBIT Margin (2023 - 2025)
Coya Therapeutics (COYA) has disclosed EBIT Margin for 3 consecutive years, with 304.74% as the latest value for Q4 2025.
- Quarterly EBIT Margin fell 50651852.0% to 304.74% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 56.09% through Dec 2025, up 3609.0% year-over-year, with the annual reading at 56.09% for FY2025, 3609.0% up from the prior year.
- EBIT Margin hit 304.74% in Q4 2025 for Coya Therapeutics, up from 68.26% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 506823.26% in Q4 2024 to a low of 4322.84% in Q1 2024.
- Historically, EBIT Margin has averaged 61971.91% across 3 years, with a median of 81.37% in 2024.
- Biggest five-year swings in EBIT Margin: skyrocketed 50679302bps in 2024 and later plummeted -50651852bps in 2025.
- Year by year, EBIT Margin stood at 30.24% in 2023, then soared by 1675822bps to 506823.26% in 2024, then plummeted by -100bps to 304.74% in 2025.
- Business Quant data shows EBIT Margin for COYA at 304.74% in Q4 2025, 68.26% in Q3 2025, and 3920.47% in Q2 2025.